Pharmacological management of erectile dysfunction

F. Montorsi, A. Salonia, F. Deho', A. Cestari, G. Guazzoni, P. Rigatti, C. Stief

Research output: Contribution to journalArticle

Abstract

Erectile dysfunction (ED)is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.

Original languageEnglish
Pages (from-to)446-454
Number of pages9
JournalBJU International
Volume91
Issue number5
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Erectile Dysfunction
Pharmacology
Phosphodiesterase 5 Inhibitors
Safety
Drug Therapy
Dopamine D1 Receptors
Dopamine D2 Receptors
Apomorphine
Alprostadil
Marketing
Pharmaceutical Preparations
Therapeutics
Injections

ASJC Scopus subject areas

  • Urology

Cite this

Pharmacological management of erectile dysfunction. / Montorsi, F.; Salonia, A.; Deho', F.; Cestari, A.; Guazzoni, G.; Rigatti, P.; Stief, C.

In: BJU International, Vol. 91, No. 5, 03.2003, p. 446-454.

Research output: Contribution to journalArticle

Montorsi, F, Salonia, A, Deho', F, Cestari, A, Guazzoni, G, Rigatti, P & Stief, C 2003, 'Pharmacological management of erectile dysfunction', BJU International, vol. 91, no. 5, pp. 446-454. https://doi.org/10.1046/j.1464-410X.2003.04093.x
Montorsi, F. ; Salonia, A. ; Deho', F. ; Cestari, A. ; Guazzoni, G. ; Rigatti, P. ; Stief, C. / Pharmacological management of erectile dysfunction. In: BJU International. 2003 ; Vol. 91, No. 5. pp. 446-454.
@article{6cebb5df833d4383bc9f9d5f5b446bcb,
title = "Pharmacological management of erectile dysfunction",
abstract = "Erectile dysfunction (ED)is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.",
author = "F. Montorsi and A. Salonia and F. Deho' and A. Cestari and G. Guazzoni and P. Rigatti and C. Stief",
year = "2003",
month = "3",
doi = "10.1046/j.1464-410X.2003.04093.x",
language = "English",
volume = "91",
pages = "446--454",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Pharmacological management of erectile dysfunction

AU - Montorsi, F.

AU - Salonia, A.

AU - Deho', F.

AU - Cestari, A.

AU - Guazzoni, G.

AU - Rigatti, P.

AU - Stief, C.

PY - 2003/3

Y1 - 2003/3

N2 - Erectile dysfunction (ED)is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.

AB - Erectile dysfunction (ED)is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.

UR - http://www.scopus.com/inward/record.url?scp=0037349838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037349838&partnerID=8YFLogxK

U2 - 10.1046/j.1464-410X.2003.04093.x

DO - 10.1046/j.1464-410X.2003.04093.x

M3 - Article

C2 - 12603396

AN - SCOPUS:0037349838

VL - 91

SP - 446

EP - 454

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -